|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...145146147148149150151152153154155156157» |
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) (clinicaltrials.gov) - Sep 28, 2011
P=N/A, N=300, Completed, Sponsor: Biogen Idec
Recruiting --> Completed
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 27, 2011
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
- || New P3 trial: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Sep 26, 2011
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: PASSION: Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP) (clinicaltrials.gov) - Sep 26, 2011
P=N/A, N=1500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Not yet recruiting --> Recruiting
- Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial termination: Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-? Blockers (clinicaltrials.gov) - Sep 26, 2011
P2, N=16, Terminated, Sponsor: Sanofi
Not yet recruiting --> Recruiting Completed --> Terminated; Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns
- | JNJ-39758979 / J&J
New P1 trial: A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants (clinicaltrials.gov) - Sep 26, 2011
P1, N=21, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Enrollment change: Nerve Conduction Velocity in Diabetic Children (clinicaltrials.gov) - Sep 25, 2011
P=N/A, N=40, Completed, Sponsor: Landeskrankenhaus Feldkirch
Completed --> Terminated; Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns N=60 --> 40
- Simulect (basiliximab) / Novartis, Lisofylline / Islet Sci
Enrollment closed: Strategies to Improve Islet Survival (clinicaltrials.gov) - Sep 25, 2011
P2, N=5, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=60 --> 40 Recruiting --> Active, not recruiting
- Trial completion: Nerve Conduction Velocity in Diabetic Children (clinicaltrials.gov) - Sep 25, 2011
P=N/A, N=40, Completed, Sponsor: Landeskrankenhaus Feldkirch
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Safety and Tolerability of Rituximab in Neuromyelitis Optica (clinicaltrials.gov) - Sep 25, 2011
P1, N=20, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Tysabri (natalizumab) / Biogen, Royalty
New P2/3 trial: Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Sep 22, 2011
P2/3, N=90, Recruiting, Sponsor: Biogen Idec
- | Benlysta (belimumab) / GSK
New P2 trial: A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. (clinicaltrials.gov) - Sep 22, 2011
P2, N=48, Not yet recruiting, Sponsor: GlaxoSmithKline
- atacicept (VT-001) / Vera Therap
New P2 trial: EMR 700461-018: Atacicept Demonstrating Dose RESponSe (clinicaltrials.gov) - Sep 22, 2011
P2, N=0, Withdrawn, Sponsor: EMD Serono
- ||| Trial completion: Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey (clinicaltrials.gov) - Sep 22, 2011
P=N/A, N=356, Completed, Sponsor: Abbott
Active, not recruiting --> Completed Recruiting --> Completed
- New P2 trial: Closing the Loop in Adults With Type 1 Diabetes in the Home Setting (clinicaltrials.gov) - Sep 22, 2011
P2, N=24, Completed, Sponsor: University of Cambridge
- |||||| Cosentyx (secukinumab) / Novartis
Enrollment open: NURTURE 1: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor ? (Anti-TNF?) Agents (CAIN457F2309 and CAIN457F2309E1) (clinicaltrials.gov) - Sep 22, 2011
P3, N=548, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- GlucaGen (recombinant glucagon) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone (clinicaltrials.gov) - Sep 22, 2011
P2, N=14, Completed, Sponsor: Legacy Health System
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial withdrawal: Assessment of the Disease Severity and Treatment Patterns of Rheumatoid Arthritis in Eastern Europe, Middle East and North African Countries (P08167) (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=10000, Withdrawn, Sponsor: Schering-Plough
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- ||| Promacta (eltrombopag) / Novartis
Clinical: Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=280, Completed, Sponsor: GlaxoSmithKline
- ||| Orencia (abatacept) / BMS
New P1 trial: Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb (clinicaltrials.gov) - Sep 21, 2011
P1, N=223, Completed, Sponsor: Bristol-Myers Squibb
- |||||| Cosentyx (secukinumab) / Novartis
Enrollment open: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNF? Agents (clinicaltrials.gov) - Sep 21, 2011
P3, N=630, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- ||| Doptelet (avatrombopag) / SOBI
New P3 trial: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) - Sep 20, 2011
P3, N=49, Completed, Sponsor: Eisai Inc.
- ||||| Saphnelo (anifrolumab) / AstraZeneca
New P2 trial: MUSE: A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 20, 2011
P2, N=571, Active, not recruiting, Sponsor: MedImmune LLC
- Trial completion: PROFIL: Study of 24 Hour Blood Pressure and the Association to Complications to Type 1 Diabetes (clinicaltrials.gov) - Sep 20, 2011
P=N/A, N=650, Completed, Sponsor: Steno Diabetes Center
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Trial completion: A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 20, 2011
P1, N=60, Completed, Sponsor: Genentech
Recruiting --> Completed Active, not recruiting --> Completed
- | dalfampridine / Generic mfg.
New P2 trial: Dalfampridine for Imbalance in Multiple Sclerosis (clinicaltrials.gov) - Sep 19, 2011
P2, N=24, Active, not recruiting, Sponsor: Oregon Health and Science University
- |||| Plivensia (sirukumab) / J&J
Trial completion: A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Sep 19, 2011
P2, N=187, Completed, Sponsor: Centocor, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tzield (teplizumab-mzwv) / Sanofi
Enrollment change: MGA031, Sirolimus and Tacrolimus in Islet Transplantation (clinicaltrials.gov) - Sep 19, 2011
P1/2, N=5, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed N=12 --> 5
- ||||| New P4 trial: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Sep 18, 2011
P4, N=54, Completed, Sponsor: Novartis Pharmaceuticals
- Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Enrollment change: Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 18, 2011
P4, N=20, Completed, Sponsor: Command Hospital, India
N=12 --> 5 N=50 --> 20
- Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment change, Combination therapy: A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 18, 2011
P1, N=29, Completed, Sponsor: Hoffmann-La Roche
N=50 --> 20 N=24 --> 29
- | Doptelet (avatrombopag) / SOBI
New P1 trial: Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. (clinicaltrials.gov) - Sep 18, 2011
P1, N=36, Completed, Sponsor: Eisai Inc.
- | tabalumab (LY2127399) / Eli Lilly
Trial completion: A Study for Japanese Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 18, 2011
P1, N=32, Completed, Sponsor: Eli Lilly and Company
N=24 --> 29 Active, not recruiting --> Completed
- Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Trial completion: Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 18, 2011
P4, N=20, Completed, Sponsor: Command Hospital, India
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- | Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion, Combination therapy: A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 18, 2011
P1, N=29, Completed, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Completed Recruiting --> Completed
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Sep 18, 2011
P3, N=132, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: PLACATE-MS: Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS (clinicaltrials.gov) - Sep 15, 2011
P2, N=20, Terminated, Sponsor: University of Rochester
Active, not recruiting --> Completed Enrolling by invitation --> Terminated; funding stopped due to slow enrollment.
- Enrollment change, IO biomarker: Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) (clinicaltrials.gov) - Sep 15, 2011
P1/2, N=6, Completed, Sponsor: Koneti Rao
Enrolling by invitation --> Terminated; funding stopped due to slow enrollment. N=12 --> 6
- Preclinical: Metal Ions in Ceramic on Metal Total Hip Arthroplasty (clinicaltrials.gov) - Sep 15, 2011
P=N/A, N=83, Not yet recruiting, Sponsor: Hussain Kazi
- | Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P2 trial: TIV and High Dose TIV in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 15, 2011
P2, N=102, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Trial completion, IO biomarker: Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) (clinicaltrials.gov) - Sep 15, 2011
P1/2, N=6, Completed, Sponsor: Koneti Rao
N=12 --> 6 Recruiting --> Completed
- ||||||| glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Trial completion: CONFIRM: Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 14, 2011
P3, N=1232, Completed, Sponsor: Biogen Idec
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: BPK003: Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=44, Completed, Sponsor: University of Virginia
Active, not recruiting --> Completed N=120 --> 44
- Trial completion: BPK003: Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=44, Completed, Sponsor: University of Virginia
N=120 --> 44 Active, not recruiting --> Completed
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
New P3 trial: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Sep 12, 2011
P3, N=24, Terminated, Sponsor: Eisai Inc.
- Trial completion: BPK002: Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes (clinicaltrials.gov) - Sep 12, 2011
P=N/A, N=120, Completed, Sponsor: Boris Kovatchev, PhD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cosentyx (secukinumab) / Novartis
New P2 trial: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 11, 2011
P2, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| New P4 trial: Correlation Between Beliefs About Medicine and Objective Measures of Efficacy and Safety in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 11, 2011
P4, N=500, Recruiting, Sponsor: Pfizer
- | Olumiant (baricitinib) / Incyte, Eli Lilly
Trial completion: A Relative Bioavailability and Food Effect Study of New Formulations (clinicaltrials.gov) - Sep 11, 2011
P1, N=16, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Using Glucose Sensors to Prevent Hypoglycemia (clinicaltrials.gov) - Sep 11, 2011
P3, N=16, Completed, Sponsor: University of Alberta
Recruiting --> Completed Active, not recruiting --> Completed